Abstract Number: 0424 • ACR Convergence 2020
Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis
Background/Purpose: Relapsing polychondritis (RP) is a highly heterogenous systemic inflammatory disorder that affects many organ systems, in particular, cartilaginous structures. Clinical presentations in RP are…Abstract Number: 1422 • ACR Convergence 2020
Healthcare Utilization Among Patients Diagnosed with ANCA-Associated Vasculitis Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data
Background/Purpose: ANCA-associated vasculitis (AAV) leads to complications that contribute to poor quality of life and survival. Systemic vasculitis is associated with high healthcare utilization but…Abstract Number: 1688 • ACR Convergence 2020
Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study
Background/Purpose: The incidence of Kawasaki disease (KD) is increasing in Ontario. Cardiovascular sequelae following KD are well-described. However, there are limited and conflicting non-cardiovascular outcome…Abstract Number: 1947 • ACR Convergence 2020
Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis affecting patients aged above 50 years. Its clinical manifestations such as headache, jaw claudication…Abstract Number: 0425 • ACR Convergence 2020
MAGIC Syndrome in a Cohort of Patients with Relapsing Polychondritis
Background/Purpose: Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome is an extremely rare condition that encompasses symptoms of relapsing polychondritis (RP) and Behcet’s disease…Abstract Number: 1423 • ACR Convergence 2020
Declining In-Hospital Mortality in Vasculitis: A 17-year U.S. National Study
Background/Purpose: To our knowledge, only a few population-based studies for vasculitis mortality exist; and most are limited to vasculitis sub-types. Therefore, our study objective was…Abstract Number: 1690 • ACR Convergence 2020
Henoch-Schönlein Purpura Nephritis: Different Histological Classifications, but Which One Is Most Strongly Associated to the Outcome of the Disease? Pilot Study of the Paediatric Rheumatology European Society Vasculitis Working Party
Background/Purpose: Henoch-Schönlein purpura nephritis (HSPN) is the main and almost the only cause of morbidity and mortality among children suffering from this most common vasculitis…Abstract Number: 1953 • ACR Convergence 2020
Somatic Mutations in a Single Residue of UBA1 Cause VEXAS, a Severe Adult-Onset Rheumatic Disease Presenting as Relapsing Polychondritis, Polyarteritis Nodosa, or Giant Cell Arteritis
Background/Purpose: Identifying the causes of adult-onset rheumatic diseases remains a challenge, and limits diagnosis, prognosis, and targeted treatment. We hypothesized that mutations in genes regulating…Abstract Number: 0428 • ACR Convergence 2020
Enrichment of Clinical Trial Recruitment Using Advanced Molecular Imaging in Takayasu’s Arteritis
Background/Purpose: Definitions of disease activity are not standardized in Takayasu’s arteritis (TAK), which can lead to difficulty in determining whether a patient should be enrolled…Abstract Number: 1427 • ACR Convergence 2020
Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) – An 18 Month Follow-up Study as a Steroid Sparing Therapeutic Approach
Background/Purpose: EGPA is a small vessel vasculitis characterized by the presence of tissue eosinophilia, necrotizing vasculitis and granulomatous inflammation1. In the randomized, placebo-controlled MIRRA trial…Abstract Number: 1691 • ACR Convergence 2020
Applied Geostatistics in Pediatric Rheumatology – Spatial Clustering of IgA Vasculitis
Background/Purpose: IgA vasculitis (IgAV) is the most common childhood vasculitis, which etiology seems to be related to the combination of genetic as well as environmental…Abstract Number: 1959 • ACR Convergence 2020
Epidemiology of Hospitalizations and Associated Mortality in Vasculitis: A National Study
Background/Purpose: To assess whether comorbid diseases frequently associated with primary hospitalizations for non-vasculitis causes in people with vasculitis are changing over time in people with…Abstract Number: 0452 • ACR Convergence 2020
Recombinant Zoster Vaccine in Patients with Rheumatic Diseases: A Retrospective Study of 622 Patients
Background/Purpose: The recombinant herpes zoster vaccine (RZV) was FDA-approved in 2017 but patients with rheumatic diseases were excluded from initial pivotal trials because of theoretical…Abstract Number: 1428 • ACR Convergence 2020
The Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Background/Purpose: Tocilizumab (TCZ) has been proven to be safe and effective for the treatment of giant cell arteritis (GCA) in 2 randomized controlled trials; however,…Abstract Number: 1919 • ACR Convergence 2020
Efficacy & Safety of Tocilizumab in Giant Cell Arteritis: A Single Centre NHS Experience Using Imaging (Ultrasound and PET CT) as a Diagnostic and Monitoring Tool
Background/Purpose: Tocilizumab (TCZ), an IL-6 receptor blocker is approved to treat relapsing, refractory Giant cell arteritis (GCA) We here report our real-life clinical experience with…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 35
- Next Page »